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in Myocardial Infarction?
Or Just Stent All Lesions?*
Deepak L. Bhatt, MD, MPHSEE PAGE 963P rimary percutaneous coronary intervention(PCI), where available, is the clear treatmentof choice for ST-segment myocardial infarc-
tion (STEMI) (1). A major controversy is whether to
only treat the culprit lesion or to also treat obstructive
nonculprit lesions—and when. Many interventional-
ists believe that treating all signiﬁcant lesions would
provide clinical beneﬁt, but recent guidelines and
reimbursement patterns have discouraged this (2).
The PRAMI (Preventive Angioplasty in Acute Myocar-
dial Infarction) trial addressed this question in 465
patients and found an w65% reduction in ischemic
events with complete revascularization during the
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research for FlowCo, PLx Pharma, and Takeda.well-done but modestly sized trial, such as whether
it was necessary to complete the revascularization
during the index procedure or whether it could be
staged during the index hospitalization.In this issue of the Journal, Gershlick et al. (4) have
published the primary results of CvLPRIT (Complete
versus Lesion-only Primary PCI Trial), which ran-
domized 296 patients with STEMI to complete versus
culprit lesion–only revascularization. They found a
signiﬁcant reduction in the primary endpoint of
mortality, recurrent myocardial infarction (MI), heart
failure, or ischemia-driven revascularization within
12 months with complete versus culprit-only revas-
cularization (10.0% vs. 21.2%; hazard ratio: 0.45;
p ¼ 0.009). The reduction in the primary endpoint
was evident early, within the ﬁrst 30 days (p ¼ 0.055).
There was a trend toward greater beneﬁt in the
approximately two-thirds of patients in whom
revascularization was completed during the index
procedure versus later during the index hospitaliza-
tion. The study was not powered for individual end-
points, although all were consistently lower in the
complete revascularization group.
Pooled data from international randomized clinical
trials show that approximately 50% of patients with
STEMI have obstructive disease ($50% stenosis) in a
nonculprit artery (5). Furthermore, there was an
approximately 50% excess in 30-day mortality associ-
ated with the presence of obstructive nonculprit ste-
noses in this pooled analysis, which remained on
adjusted analyses, which implies that “ﬁxing” these
nonculprit stenoses very early should decrease 30-day
mortality. The early beneﬁts noted in CvLPRIT lend
support to this concept. Perhaps, these seemingly sta-
ble nonculprit plaques are trouble waiting to happen.
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data from the SHOCK (Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic
Shock) trial provided a strong basis for complete
revascularization (6). Many interventionalists ex-
trapolated those results to patients with STEMI and
multivessel disease but without shock. In contrast,
observational data suggested that this approach was
not beneﬁcial and might be harmful (7), although
with the possibility of differential effects depending
on the exact timing of the nonculprit PCI (8). How-
ever, despite sophisticated statistical adjustment,
nonrandomized analyses can never fully account for
unmeasured confounders that may have caused the
operator to perform the multivessel PCI, such as the
“eyeball test,” in which the patient appears ill in ways
that are difﬁcult to capture on a case report form.
Therefore, in contradistinction to the non-
randomized data, we have 2 rigorously performed,
albeit modestly sized, contemporary randomized
clinical trials, PRAMI and now CvLPRIT, which ﬁnd
substantial beneﬁt from complete revascularization in
STEMI patients. Formal patient-level meta-analyses
will surely be performed and will likely corroborate
the beneﬁcial ﬁndings seen in the individual trials
(Figure 1). Nevertheless, because the overall sample
size will remain modest, the observed degree of
beneﬁt may be an overestimation. Still, given the
ﬁndings of these 2 trials, even if the experiment wereFIGURE 1 Pooled Analysis of CvLPRIT and PRAMI Trial-Level
Data for Cardiac Death, MI, and Revascularization
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Boxes represent hazard ratios (HR); lines represent 95% conﬁ-
dence intervals. CvLPRIT ¼ Complete versus Lesion-only Primary
PCI Trial; MI ¼ myocardial infarction; PRAMI ¼ Preventive
Angioplasty in Acute Myocardial Infarction.repeated, it is unlikely that the complete revasculari-
zation approach would be found harmful.
The debate over whether to stent nonculprit le-
sions in STEMI has occurred in a larger context. After
the COURAGE (Clinical Outcomes Utilizing Revascu-
larization and Aggressive Drug Evaluation) trial, there
has been a swing to treat nonacute lesions more
conservatively (9). Using fractional ﬂow reserve
guidance in stable lesions, FAME 2 (Fractional Flow
Reserve versus Angiography for Multivessel Evalua-
tion 2) showed a reduction in death or MI in land-
mark analyses after discounting periprocedural
events during the ﬁrst week (10). Although the num-
ber of events was low, the FAME 2 data support the
concept that stenting severe ischemia-causing lesions
in stable patients not only reduces the need for future
urgent revascularization but may also reduce death or
MI. The ongoing ISCHEMIA (International Study of
Comparative Health Effectiveness With Medical and
Invasive Approaches) trial (11) should provide further
insight into the impact of stenting stable lesions.
The older SWISSI II trial (Swiss Interventional
Study on Silent Ischemia Type II) found that in 201
patients with recent MI and silent ischemia, those
randomized to full percutaneous revascularization
had a lower major adverse cardiac event rate than
those treated medically (12). Thus, the question of
whether to treat “stable” lesions in STEMI patients
might be quite different from whether to treat “sta-
ble” lesions in stable patients. Patients with STEMI
have already demonstrated the ability to rupture
plaque and form occlusive thrombus once and may be
more likely to do it again, potentially in the short
term. Thus, they may represent a different phenotype
from those with severe stable plaque but no prior
ischemic events.
The large, ongoing COMPLETE (Complete vs.
Culprit-only Revascularization to Treat Multi-vessel
Disease After Primary PCI for STEMI) trial (13), pow-
ered for cardiovascular death or MI, will provide a
more detailed evaluation of the question of complete
versus culprit revascularization, although differences
in study design may limit direct comparisons. The
role of fractional ﬂow reserve in potentially reﬁning
the treatment of the nonculprit lesions merits further
study, although lesion stability, as well as lesion
severity, may need assessment. How the results
of PRAMI and CvLPRIT should be interpreted in non-
STEMI remains an open question (14). Second-
generation and third-generation drug-eluting stents
may further favorably affect the balance toward
more aggressive revascularization (15). Many inter-
ventionalists will ﬁnd the CvLPRIT data consistent
with their preexisting beliefs and the data compelling
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975enough to change practice. In contrast, trialists and
guideline writing committees will probably demand
further randomized data to provide more robust es-
timates of beneﬁt, more deﬁnitively evaluate effects
on “hard” outcomes (Figure 1), and resolve issues
regarding the exact timing and nature of the complete
revascularization.
For now, a very reasonable approach would incor-
porate clinical judgment. In a patient with STEMI
undergoing primary PCI who is in borderline cardio-
genic shock—in whom the numbers do not really meet
the deﬁnition, but the blood pressure is low, for
example—complete revascularization during the
initial procedure may make good sense. In a hemo-
dynamically stable patient with relief of chest pain
after stenting the culprit right coronary artery lesion,
it may be prudent to defer treatment of a complex
left-sided bifurcation lesion until later in the hospi-
talization. Factoring in hemodynamic status, renalfunction, lesion severity/complexity, left ventricular
function, vascular access/bleeding risk, and time of
day/night may be the most appropriate way to
determine whether to treat the nonculprit lesion(s)
during the initial procedure or later during the hos-
pitalization, or to defer treatment decisions to the
outpatient setting, while awaiting the accrual of
additional trial data.
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